DRI Healthcare Trust is engaged in pharmaceutical royalty monetization by providing capital to inventors, academic institutions, and biopharma companies. Trust was formed to provide Unitholders with differential exposure to the pharmaceutical and biotechnology industries through ownership and acquisitions of pharmaceutical royalties. In return for providing capital to biopharmaceutical innovators, the company is building a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world. The Trust has concluded that it operates as one segment, primarily focused on acquiring royalty assets. Geographically the trust generates major revenue from the United States. The trust also generates Income from markets such as Japan, and the European Union.